Latest News and Press Releases
Want to stay updated on the latest news?
-
Delhi, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Global Proteolysis Targeting Chimeras PROTAC Therapy Clinical Trials Insight & Market Opportunity Report Highlights: First PROTAC Drug Approval Expected...
-
Delhi, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Global Proteolysis Targeting Chimeras PROTAC Therapy Clinical Trials Insight & Market Opportunity Report Highlights: First PROTAC Drug Approval...
-
Delhi, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development...
-
Delhi, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Brazil Cancer Drugs Clinical Trials Insight 2024 Report Offering: Brazil Clinical Trials Market Opportunity 2024 and 2030 (In US$ Million)Clinical Trials...
-
Delhi, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Global LAG-3 Inhibitors Market, Drug Sales, & Clinical Trials Insight 2029 Report Highlights: Global LAG-3 Inhibitors Market Opportunity: > USD 3...
-
Delhi, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Global mRNA Cancer Vaccines Clinical Trials and Market Future Outlook 2024 Report Highlights: mRNA Cancer Vaccines In Clinical Trials: > 60...
-
Delhi, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity and Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: > 20...
-
Delhi, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development...
-
Delhi, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 Report Highlights Global & Regional Market Opportunity...
-
Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership...